Neurocrine Biosciences Cash Flow From Operations vs. Current Valuation

N1BI34 Stock   38.16  0.65  1.73%   
Based on Neurocrine Biosciences' profitability indicators, Neurocrine Biosciences may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Neurocrine Biosciences' ability to earn profits and add value for shareholders.
For Neurocrine Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurocrine Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurocrine Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurocrine Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurocrine Biosciences over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Neurocrine Biosciences Current Valuation vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Neurocrine Biosciences's current stock value. Our valuation model uses many indicators to compare Neurocrine Biosciences value to that of its competitors to determine the firm's financial worth.
Neurocrine Biosciences is considered to be number one stock in cash flow from operations category among its peers. It also is rated top company in current valuation category among its peers reporting about  226.87  of Current Valuation per Cash Flow From Operations. Comparative valuation analysis is a catch-all model that can be used if you cannot value Neurocrine Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neurocrine Biosciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Neurocrine Current Valuation vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Neurocrine Biosciences

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
256.5 M
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Neurocrine Biosciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
58.19 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Neurocrine Current Valuation vs Competition

Neurocrine Biosciences is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers-Specialty & Generic industry is now estimated at about 3.25 Trillion. Neurocrine Biosciences claims roughly 58.19 Billion in current valuation contributing just under 2% to equities under Drug Manufacturers-Specialty & Generic industry.

Neurocrine Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Neurocrine Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurocrine Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurocrine Biosciences' important profitability drivers and their relationship over time.

Use Neurocrine Biosciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurocrine Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will appreciate offsetting losses from the drop in the long position's value.

Neurocrine Biosciences Pair Trading

Neurocrine Biosciences Pair Trading Analysis

The ability to find closely correlated positions to Neurocrine Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurocrine Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurocrine Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurocrine Biosciences to buy it.
The correlation of Neurocrine Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurocrine Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurocrine Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurocrine Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Neurocrine Biosciences position

In addition to having Neurocrine Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Online Gaming Thematic Idea Now

Online Gaming
Online Gaming Theme
Companies that are involved in the building and marketing of online gaming-related products. The Online Gaming theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Online Gaming Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Neurocrine Stock

When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:
Check out Correlation Analysis.
For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
To fully project Neurocrine Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neurocrine Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neurocrine Biosciences' income statement, its balance sheet, and the statement of cash flows.
Potential Neurocrine Biosciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Neurocrine Biosciences investors may work on each financial statement separately, they are all related. The changes in Neurocrine Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neurocrine Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.